HeartSciences Inc. (HSCS)

HeartSciences' stock has been impacted by several events in the past six months. On December 15, 2025, the company released its Q2 2026 earnings, reporting an EPS of -$0.85, which surpassed analysts' consensus estimates of -$0.90, and quarterly revenue was reported at $2.42 million, exceeding the consensus estimate of $0 million. HeartSciences' stock underwent a 1-for-100 reverse stock split on May 17, 2024. Over the past year, the stock price has fluctuated between a low of $2.01 and a high of $6.47.

Based on historical stock price data, HeartSciences has shown some demand seasonality. May has historically offered the highest probability of positive returns for the stock at 66.67%, while January may not be an ideal month to invest in HSCS, with a 25.00% probability of a positive return.

HeartSciences, Inc. is an AI-powered medical technology company focused on enhancing ECG utility for earlier detection of heart disease. It operates in the Healthcare sector, specifically Medical Devices & Instruments, and aims to transform ECGs into valuable cardiac screening tools. Its major products include AI-ECG diagnostic solutions, the MyoVista Insights cloud-platform, and the MyoVista wavECG Device. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024.

HeartSciences, Inc. is headquartered in Southlake, Texas, and its technology has received regulatory clearance in the United States and the European Union. The company is focused on developing solutions to enable earlier detection of heart disease and improve patient outcomes worldwide.

HeartSciences has seen positive developments impacting its brand reputation in the past year. The University of West England adopted HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to establish an ECG Education and Technology Reference Center. A partnership between HeartSciences and Mount Sinai Hospital has been highlighted as validating the efficacy of MyoVista and facilitating its widespread adoption and commercialization. The company also announced a major upgrade to user features of its MyoVista Insights Platform with the commercial launch of Version 1.1 on December 11, 2025. Analysts currently have a "Hold" consensus rating for HeartSciences.

HeartSciences Inc. has 16 institutional owners and shareholders holding a total of 184,637 shares. Major institutional shareholders include DRW Securities, LLC, TFB Advisors LLC, Astoria Strategic Wealth, Inc., Vanguard Group Inc, and Geode Capital Management, Llc. Institutional investors own approximately 4.17% to 17.24% of the company's stock. CEO Andrew Simpson directly owns 2.34% of the company's shares. Retail investors hold approximately 92.93% of the stock.